CN105695400A - 一种纯化干细胞来源的心肌细胞的无血清培养基 - Google Patents

一种纯化干细胞来源的心肌细胞的无血清培养基 Download PDF

Info

Publication number
CN105695400A
CN105695400A CN201610163672.3A CN201610163672A CN105695400A CN 105695400 A CN105695400 A CN 105695400A CN 201610163672 A CN201610163672 A CN 201610163672A CN 105695400 A CN105695400 A CN 105695400A
Authority
CN
China
Prior art keywords
serum
free medium
cell
stem cell
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610163672.3A
Other languages
English (en)
Inventor
刘�文
周向前
王志敏
陈志辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Yougeen Biological Technology Co Ltd
Shanghai Industrial Institute For Research And Technology
Original Assignee
Shanghai Yougeen Biological Technology Co Ltd
Shanghai Industrial Institute For Research And Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Yougeen Biological Technology Co Ltd, Shanghai Industrial Institute For Research And Technology filed Critical Shanghai Yougeen Biological Technology Co Ltd
Priority to CN201610163672.3A priority Critical patent/CN105695400A/zh
Publication of CN105695400A publication Critical patent/CN105695400A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657Cardiomyocytes; Heart cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • C12N2500/32Amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • C12N2500/34Sugars
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • C12N2500/38Vitamins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • C12N2500/40Nucleotides, nucleosides or bases
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/90Serum-free medium, which may still contain naturally-sourced components
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30Hormones
    • C12N2501/33Insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

本发明属于生物技术细胞培养技术领域,具体为一种纯化干细胞来源的心肌细胞的无血清培养基。其组分包括:L-谷氨酰胺、胰岛素、维生素、基因重组人血白蛋白、氨基酸、非必需氨基酸、微量元素、乳糖、槲皮素、溴脱氧核苷、RPMI无糖培养基;其中,L-谷氨酰胺0.1-5mmol/L、胰岛素2-10mmol/L、维生素A 0-800μg/mL、维生素C(L-抗坏血酸-2-磷酸酯)100-300μg/mL、基因重组人血白蛋白0.1-2mg/mL、氨基酸0.1%-5%、非必需氨基酸1%-5%、微量元素0.1%-0.5%。该培养基可以帮助提纯混合体系的心肌细胞,其他的非心肌细胞在细胞混合物中比例逐渐降低,最后获得纯度高的心肌细胞。此培养基不含血,避免了病毒污染造成的危害。

Description

一种纯化干细胞来源的心肌细胞的无血清培养基
技术领域
本发明属于生物细胞培养技术领域,具体涉及一种纯化干细胞来源的心肌细胞的无血清培养基。
背景技术
细胞是生命的基本单位,犹如分子是物质的基本单位一样,细胞的功能决定了器官以及组织的功能,器官组织再构成了生命体。细胞生物学作为研究细胞的科学,研究细胞的结构,功能以及代谢、凋亡等特征和规律的一门科学。
而细胞培养技术则是在细胞生物学中最重要和最基础的技术方法手段,细胞培养是将细胞在体外环境条件下生长。细胞培养可以将细胞传代,体外培养以获得科学研究所需数量和质量的细胞,同时可以达到对细胞数量的扩增,细胞族群的筛选,细胞发育状态的变化等等目标。目前,细胞培养广泛的在生物制药、分子生物学、药物开发、医学临床上面获得应用。
在细胞培养的过程中,利用不同的培养基成分,结合特定细胞代谢特性,对特定的细胞群进行筛选,是纯化特定细胞群的方法。
心肌细胞是心脏组织的重要组成部分,数量上占心脏组织所有细胞总数的60%以上。心肌细胞的体外培养在心血管疾病研究中占据重要作用。心肌细胞可以从干细胞通过诱导分化的方式获得。干细胞是一种具有分化潜能的细胞,多种类型的干细胞均可以分化成为心肌细胞。而这些干细胞在体外特定因子诱导下变成心肌细胞和各个不同发育阶段的细胞混合物后,心肌细胞具有自发的节律性和收缩的特性。在体外分化培养过程中,很多成熟的心肌细胞的特征已经被观测到,结合现代生物技术的很多方法,如特异性抗体标记后荧光显色,电生理测试等技术手段来定性和定量的检测心肌细胞。
现有科技条件下,体外细胞培养,包括干细胞和心肌细胞的培养,大多数情况下都会用到牛血清,但是牛血清因为其成分的不确定性和外源病毒和致病因子风险,在未来细胞的临床使用中是隐患性的问题。而且牛血清产品由于不同批次以及厂家不同带来的差异太大。因此,用确定化学组分的培养基添加剂代替血清的作用,构建无血清培养基,是更优的选择方案。
发明内容
本发明的目的在于提供一种能够获得高纯度心肌细胞、且可避免病毒污染造的纯化干细胞来源的心肌细胞的无血清培养基。
本发明的培养基,可将从干细胞来源的心肌细胞从这个诱导反应获得的细胞混合物中提纯出来,让细胞种群变成单一性的心肌细胞,而去除其他未分化的细胞或者分化阶段未达到最终心肌细胞阶段的细胞,使得这个混合体系里面的心肌细胞成分中心肌细胞的比重尽量更大甚至达到纯净的心肌细胞状态。
本发明提出的纯化干细胞来源的心肌细胞的无血清培养基,其组分包括:L-谷氨酰胺、胰岛素、维生素、基因重组人血白蛋白、氨基酸、非必需氨基酸、微量元素、乳糖、槲皮素、溴脱氧核苷、RPMI无糖培养基;以RPMI无糖培养基500mL为基础,各组份的量为:
L-谷氨酰胺0.1-5mmol/L;
胰岛素2-10mmol/L;
维生素A0-800μg/mL,维生素C(L-抗坏血酸-2-磷酸酯)100-300μg/mL;
基因重组人血白蛋白0.1-2mg/mL;
氨基酸0.1%-5%;
非必需氨基酸1%-5%;
微量元素0.1%-0.5%;
乳糖的浓度为3mmol/L-5mmol/L;
槲皮素的浓度为0-10mmol/L;
溴脱氧核苷0-0.5mmol/L。
本发明中,所述的氨基酸选自L-精氨酸、L-胱氨酸、L-组氨酸、L-异亮氨酸、L-亮氨酸、L-赖氨酸、L-甲硫氨酸、L-苯丙氨酸、L-苏氨酸、L-色氨酸、L-酪氨酸、L-缬氨酸、L-丙氨酸、L-天冬氨酸、L-天冬酰胺、L-谷氨酸、甘氨酸、L-脯氨酸、L-丝氨酸中的一种或几种。
本发明中,所述的非必需氨基酸是指人体能够自身合成的氨基酸种类,选自甘氨酸、丙氨酸、脯氨酸、酪氨酸、丝氨酸、半胱氨酸、天冬酰胺、谷氨酰胺、天冬氨酸、谷氨酸中的一种或几种。
本发明中,所述的所述微量元素选自Cu、Zn、Se、Fe、Sn、Ni、Ag、Al、Cr、Ge、Zr、Rb、Co、Cd、Ba、K中的一种或几种。
本发明提出的纯化干细胞来源的心肌细胞的无血清培养基,其优点是:利用了心肌细胞和其他种类细胞可以利用不同种类的能量物质支持其生长所必须,将培养基成分敲除其他种类细胞必须的能量物质而替代用可以支撑心肌细胞生长的能量物质,这样在保证心肌细胞正常培养的情况下,也选择出了心肌细胞种群。同时配合对于干细胞有抑制作用的抑制剂,能够将目标细胞群更好的筛选出来。心肌纯化培养基中未使用牛血清,而是添加了血清的主要成分,能够减少血清带来的不确定性的影响,同时保证心肌细胞本身的活性。
此培养基不含血,为化学成分完全清楚,避免了病毒污染造成的危害。
具体实施方式
为使得本发明的操作达到预期目的,并使得优点更加明显易懂,下面结合具体实施方式对本发明作进一步详细的说明。
本发明的培养基,在干细胞诱导心肌的体系中,等待出现了成熟心肌的表征并伴有自发性搏动出现后,再由过程中预定时期内的培养基培养大约3到5天,之后换上维持心肌细胞的培养基培养培养3天。随后换上本发明中的培养基,每2-3天根据培养基消耗情况更换培养基,持续培养7-8天时间。
通过以上实施方式的描述,本领域的技术人员可以在常用的分化体系里面比较简单的实现提纯任务,并且由于培养基体系无血清参与,体系中无未知的因子参与以及无异源性的病毒污染风险,让培养后的细胞在使用上,有更好的临床使用潜力。
以上对本发明进行了详细介绍,是一种能够直接量化生产的产品,并且可以规范此类生产或者实验需求下的操作。
下表是500mLRPMI无糖培养基组配实施例:
组配1:
组配2
组配3
以上三组不同配方的培养基,在按照操作方法所述的培养了六天以后,经过流式细胞仪根据特异性的心肌细胞抗体TroponinT标记的细胞检测结果显示,三种培养基均提升了TroponinT表达的细胞比例。其中最后一组的表达比例最高。

Claims (4)

1.一种纯化干细胞来源的心肌细胞的无血清培养基,其特征在于,其组分为:L-谷氨酰胺、胰岛素、维生素、基因重组人血白蛋白、氨基酸、非必需氨基酸、微量元素、乳糖、槲皮素、溴脱氧核苷、RPMI无糖培养基;以RPMI无糖培养基500mL为基础,各组份的量为:
L-谷氨酰胺0.1-5mmol/L;
胰岛素2-10mmol/L;
维生素A0-800μg/mL,维生素C100-300μg/mL;
基因重组人血白蛋白0.1-2mg/mL;
氨基酸0.1%-5%;
非必需氨基酸1%-5%;
微量元素0.1%-0.5%;
乳糖的浓度为3mmol/L-5mmol/L;
槲皮素的浓度为0-10mmol/L;
溴脱氧核苷0-0.5mmol/L。
2.根据权利要求1所述的纯化干细胞来源的心肌细胞的无血清培养基,其特征在于,所述的氨基酸选自L-精氨酸、L-胱氨酸、L-组氨酸、L-异亮氨酸、L-亮氨酸、L-赖氨酸、L-甲硫氨酸、L-苯丙氨酸、L-苏氨酸、L-色氨酸、L-酪氨酸、L-缬氨酸、L-丙氨酸、L-天冬氨酸、L-天冬酰胺、L-谷氨酸、甘氨酸、L-脯氨酸、L-丝氨酸中的一种或几种。
3.根据权利要求1或2所述的纯化干细胞来源的心肌细胞的无血清培养基,其特征在于,所述的非必需氨基酸是指人体能够自身合成的氨基酸种类,选自甘氨酸、丙氨酸、脯氨酸、酪氨酸、丝氨酸、半胱氨酸、天冬酰胺、谷氨酰胺、天冬氨酸、谷氨酸中的一种或几种。
4.根据权利要求3所述的纯化干细胞来源的心肌细胞的无血清培养基,其特征在于,所述的所述微量元素选自Cu、Zn、Se、Fe、Sn、Ni、Ag、Al、Cr、Ge、Zr、Rb、Co、Cd、Ba、K中的一种或几种。
CN201610163672.3A 2016-03-19 2016-03-19 一种纯化干细胞来源的心肌细胞的无血清培养基 Pending CN105695400A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610163672.3A CN105695400A (zh) 2016-03-19 2016-03-19 一种纯化干细胞来源的心肌细胞的无血清培养基

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610163672.3A CN105695400A (zh) 2016-03-19 2016-03-19 一种纯化干细胞来源的心肌细胞的无血清培养基

Publications (1)

Publication Number Publication Date
CN105695400A true CN105695400A (zh) 2016-06-22

Family

ID=56232392

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610163672.3A Pending CN105695400A (zh) 2016-03-19 2016-03-19 一种纯化干细胞来源的心肌细胞的无血清培养基

Country Status (1)

Country Link
CN (1) CN105695400A (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106701665A (zh) * 2016-12-30 2017-05-24 东莞惠恩生物工程有限公司 人胎盘亚全能干细胞诱导分化为心肌细胞的方法及其应用
CN108456654A (zh) * 2018-02-22 2018-08-28 上海产业技术研究院 用于促进干细胞来源心肌细胞成熟的无血清培养体系
CN111454886A (zh) * 2020-05-12 2020-07-28 广东源心再生医学有限公司 一种增强型心肌细胞培养液及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2447191A (en) * 2005-12-22 2008-09-03 Es Cell Int Pte Ltd Direct differentiation of cardiomyocytes from human embryonic stem cells
WO2011160128A2 (en) * 2010-06-18 2011-12-22 Cellular Dynamics International, Inc. Cardiomyocyte medium with dialyzed serum
US20130029368A1 (en) * 2011-07-29 2013-01-31 Steven Kattman Metabolic maturation in stem cell-derived tissue cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2447191A (en) * 2005-12-22 2008-09-03 Es Cell Int Pte Ltd Direct differentiation of cardiomyocytes from human embryonic stem cells
WO2011160128A2 (en) * 2010-06-18 2011-12-22 Cellular Dynamics International, Inc. Cardiomyocyte medium with dialyzed serum
US20130029368A1 (en) * 2011-07-29 2013-01-31 Steven Kattman Metabolic maturation in stem cell-derived tissue cells
WO2013019661A1 (en) * 2011-07-29 2013-02-07 Cellular Dynamics International, Inc. Metabolic maturation in stem cell-derived tissue cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHUNHUI XU,ET AL: "Human Embryonic Stem Cell-Derived Cardiomyocytes Can Be Maintained in Defined Medium without Serum", 《STEM CELLS AND DEVELOPMENT》 *
杨雷 等: "槲皮素对过氧化氢所致体外心肌细胞损伤的保护作用", 《中国临床康复》 *
陈妍,等: "乳鼠心肌细胞的原代培养方法的改进", 《中国生物制品学杂志》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106701665A (zh) * 2016-12-30 2017-05-24 东莞惠恩生物工程有限公司 人胎盘亚全能干细胞诱导分化为心肌细胞的方法及其应用
CN108456654A (zh) * 2018-02-22 2018-08-28 上海产业技术研究院 用于促进干细胞来源心肌细胞成熟的无血清培养体系
CN111454886A (zh) * 2020-05-12 2020-07-28 广东源心再生医学有限公司 一种增强型心肌细胞培养液及其应用

Similar Documents

Publication Publication Date Title
Bissell et al. Parenchymal cells from adult rat liver in nonproliferating monolayer culture: I. Functional studies
CN103060264B (zh) 一种干细胞培养基及其应用和干细胞培养方法
Gatmaitan et al. Regulation of growth and differentiation of a rat hepatoma cell line by the synergistic interactions of hormones and collagenous substrata.
US20090035805A1 (en) C3A Serum-Free Clonal Cell Line and Methods of Use
WO2015180636A1 (zh) 人肝细胞长期维持和增殖传代培养的专用培养基和培养方法
US20200385683A1 (en) Composition and method for culturing organoids
KR20060076781A (ko) 세포 배양 배지
CN109943526B (zh) 一种促间充质干细胞增殖的无血清多肽组合物
CN105695400A (zh) 一种纯化干细胞来源的心肌细胞的无血清培养基
Paul Quiescent SV40 virus transformed 3T3 cells in culture
EP2265708B1 (en) Methods for stem cell production and therapy
JP2021518115A (ja) タンパク質生産の間の代謝酵素活性およびジスルフィド結合還元
CN105838675A (zh) 一种造血干细胞无血清培养基
Tobioka et al. Mitochondria in living cells: an analysis of movements
Rao Embryogenesis in flowering plants: recent approaches and prospects
CN105039251A (zh) 一种pH值稳定的淋巴细胞无血清培养基及其制备方法和应用
Lemonnier et al. Comparative study of extracellular amino acids in culture of human liver and fibroblastic cells
Altman et al. Somatic embryogenesis in celery: induction, control and changes in polyamines and proteins
CN1306569A (zh) 稳定化的瞬时基因表达
JP2000157260A (ja) 初代前駆脂肪細胞の分化誘導方法及びその分化用培地
Tasto et al. Towards a Continuous Production of Human Mesenchymal Stromal Cells in a Chemically Defined Medium: Opportunities and Challenges for a Robust and Scalable Expansion Process
JP2749011B2 (ja) 無血清培地で増殖継代可能な細胞およびその取得方法
Müthing et al. Microcarrier cultivation of bovine aortic endothelial cells in spinner vessels and a membrane stirred bioreactor
CN104931697A (zh) Cd248+cd8+t细胞亚群在人升主动脉瘤病变过程中的作用
Camien A microbiological method for the determination of L-and D-aspartic acids.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160622